Shaanxi Meibang Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 684.02 million compared to CNY 550.44 million a year ago. Revenue was CNY 684.02 million compared to CNY 550.44 million a year ago.

Net income was CNY 111.77 million compared to CNY 63.73 million a year ago. Basic earnings per share from continuing operations was CNY 0.82 compared to CNY 0.63 a year ago. Diluted earnings per share from continuing operations was CNY 0.82 compared to CNY 0.63 a year ago.